Prostate Cancer Patients With DNA Damage Repair Mutations May Respond to Platinum Chemo

NEW YORK – A subset of patients with metastatic castration-resistant prostate cancer (mCRPC) who harbor DNA damage repair (DDR) gene mutations may have an improved response to platinum chemotherapy compared to those without such mutations, according to a study recently published in the Journal of Clinical Oncology: Precision Oncology.